Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia

被引：30
|
作者：
Khalili, Hossein [1 ]
Shojaei, Lida [2 ]
Mohammadi, Mostafa [3 ]
Beigmohammadi, Mohammad-Taghi [3 ]
Abdollahi, Alireza [4 ]
Doomanlou, Mahsa [5 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Kermanshah Univ Med Sci, Fac Pharm, Dept Clin Pharm, Kermanshah, Iran
[3] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Intens Care Unit, Tehran, Iran
[4] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Pathol, Tehran, Iran
[5] Univ Tehran Med Sci, Cent Lab, Imam Hosp Complex, Tehran, Iran
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 09期
关键词：
Acinetobacter; ampicillin-sulbactam; colistin; pneumonia; VENTILATOR-ASSOCIATED PNEUMONIA; ACINETOBACTER-BAUMANNII; NOSOCOMIAL PNEUMONIA; AMPICILLIN-SULBACTAM; INTRAVENOUS COLISTIN; RISK-FACTORS; POLYMYXIN-B; MORTALITY; SURVEILLANCE; INFECTIONS;
D O I：
10.2217/cer-2018-0037
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii. Method: 47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes. Results: Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively. Conclusion: In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups.
引用
收藏
页码：901 / 911
页数：11
相关论文
共 50 条
  • [1] Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy
    Hiraki, Yoichi
    Yoshida, Mayumi
    Masuda, Yoko
    Inoue, Daisuke
    Tsuji, Yasuhiro
    Kamimura, Hidetoshi
    Karube, Yoshiharu
    Takaki, Kazutaka
    Kawano, Fumio
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (12) : E1234 - E1236
  • [2] Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
    Park, Jae-Min
    Yang, Kyung-Sook
    Chung, You-Seung
    Lee, Ki-Byung
    Kim, Jeong-Yeon
    Kim, Sun-Bean
    Sohn, Jang-Wook
    Yoon, Young-Kyung
    ANTIBIOTICS-BASEL, 2021, 10 (08):
  • [3] Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam
    Zalts, Ronen
    Neuberger, Ami
    Hussein, Khetam
    Raz-Pasteur, Ayelet
    Geffen, Yuval
    Mashiach, Tanya
    Finkelstein, Renato
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (01) : E78 - E85
  • [4] Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
    Park, So Yeon
    Si, Hye Jun
    Eom, Joong Sik
    Lee, Jin Seo
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (12) : 5977 - 5985
  • [5] Colistin, rifampicin, and meropenem administered as single agents in a model of pneumonia caused by a carbapenem-resistant Acinetobacter baumannii
    Cassisa, Viviane
    Joly-Guillou, Marie-Laure
    Pailhories, Helene
    Coron, Noemie
    Eveillard, Matthieu
    JOURNAL OF INFECTION, 2014, 69 (05) : 516 - +
  • [6] Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study
    Raz-Pasteur, Ayelet
    Liron, Yael
    Amir-Ronen, Reut
    Abdelgani, Siham
    Ohanyan, Astghik
    Geffen, Yuval
    Paul, Mical
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2019, 17 : 168 - 172
  • [7] Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia
    Shi, HyeJin
    Lee, Jin Seo
    Park, So Yeon
    Ko, Yousang
    Eom, Joong Sik
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 3925 - 3934
  • [8] Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro
    Yu, Lan
    Zhang, Jisheng
    Fu, Yanjun
    Zhao, Yongxin
    Wang, Yong
    Zhao, Jing
    Guo, Yuhang
    Li, Chunjiang
    Zhang, Xiaoli
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [9] In vitro efficacy of meropenem in combination with colistin, ampicillin-sulbactam against multidrug-resistant blaNDM-1-positive acinetobacter baumannii strains
    Hu, Huizheng
    Liu, Jing
    Su, Gengxun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (12): : 13251 - +
  • [10] The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii
    Katip, Wasan
    Uitrakul, Suriyon
    Oberdorfer, Peninnah
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 391 - 395
12345